Gemini Therapeutics Inc
Change company Symbol lookup
Select an option...
GMTX Gemini Therapeutics Inc
$R25IGTRI Russell 2500 Growth TR Index
QQQ Invesco QQQ Trust
PRDO Perdoceo Education Corp
DITHF DS Smith PLC
BIOL BIOLASE Inc
GOEV Canoo Inc
CHE Chemed Corp
ASTA WorldFlix Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
Go

Health Care : Biotechnology |
Company profile

Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH is a construct that express GEM103 continuously at a therapeutic level. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.

Closing Price
$3.72
Day's Change
-0.07 (-1.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.84
Day's Low
3.70
Volume
(Below Average)
Volume:
90,791

10-day average volume:
107,121
90,791
  • Prev Close
    3.79
  • Today's Open
    3.84
  • Day's Range
    3.70-3.84
  • Avg Vol (10-day)
    107.1K
  • Last (time)
    4:00p ET 10/15/21
  • Last (size)
    10
  • 52-Wk Range
    3.22 - 19.09
    LowHigh
  • (03/15/21 - 08/20/21)
    15.53%
  • 76.0%
  • Market Cap
    160.4M
  • Shares Outstanding
    43.1M
  • -1.04
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 71.00
  • (% of float 09/30/21)
    5.71

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.